Who are Consolidation, III HiDAraC cycle's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): II Consolidation HiDAraC.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/consolidation-iii-hidarac-cycle.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Consolidation, III HiDAraC cycle — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Consolidation, III HiDAraC cycle (Consolidation, III HiDAraC cycle) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog / Antimetabolite chemotherapy. Area: Oncology.

phase 3 Nucleoside analog / Antimetabolite chemotherapy DNA/RNA synthesis (cytidine deaminase inhibition pathway) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Consolidation, III HiDAraC cycle (Consolidation, III HiDAraC cycle) — dr hab. n. med. Agnieszka Wierzbowska. HiDAraC (high-dose cytarabine consolidation) is a chemotherapy regimen that delivers high doses of cytarabine to inhibit DNA synthesis and induce apoptosis in leukemic cells.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Consolidation, III HiDAraC cycle TARGET	Consolidation, III HiDAraC cycle	dr hab. n. med. Agnieszka Wierzbowska	phase 3	Nucleoside analog / Antimetabolite chemotherapy	DNA/RNA synthesis (cytidine deaminase inhibition pathway)
II Consolidation HiDAraC	II Consolidation HiDAraC	dr hab. n. med. Agnieszka Wierzbowska	phase 3	Nucleoside analog / Antimetabolite chemotherapy	DNA synthesis (cytidine deaminase inhibition pathway)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside analog / Antimetabolite chemotherapy class)

dr hab. n. med. Agnieszka Wierzbowska · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Consolidation, III HiDAraC cycle — Competitive Intelligence Brief. https://druglandscape.com/ci/consolidation-iii-hidarac-cycle. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab